India Glycols (500201) Q1 24/25 earnings summary

Executive summary

• Q1 FY25 consolidated revenue was ₹2,282.58 crore and PAT was ₹60.38 crore, versus ₹1,893.64 crore and ₹51.14 crore a year earlier.

• Bio-Fuel was the strongest growth segment; margin pressure persisted in BSPC and Ennature Biopharma.

Financial highlights

• Consolidated net revenue was ₹969 crore, up 40.6% YoY; EBITDA was ₹128.36 crore versus ₹105.81 crore.

• Consolidated profit before tax was ₹75.65 crore versus ₹63.72 crore; PAT was ₹60.38 crore versus ₹51.14 crore.

• Consolidated basic and diluted EPS was ₹19.50 versus ₹16.52 YoY.

• Consolidated finance costs were ₹35.86 crore versus ₹27.58 crore YoY.

Segment performance

• BSPC revenue was ₹392.95 crore versus ₹335.20 crore YoY; segment result was ₹35.87 crore, with a 9.9% EBIT margin.

• Bio-Fuel revenue was ₹238.99 crore versus ₹65.02 crore; segment result was ₹18.68 crore versus ₹3.11 crore, with a 7.8% EBIT margin.

• Potable Spirits revenue grew 19.1% YoY to ₹280 crore; EBIT rose 14.2% to ₹49 crore, with a 17.5% margin.

• Ennature Biopharma revenue was ₹56.81 crore versus ₹52.57 crore; segment result was ₹6.45 crore versus ₹12.79 crore, with an 11.4% EBIT margin.